Skip to main content

Table 1 Clinical characteristics of mild CD patients according to presence of bowel damage

From: Elevated C-reactive protein is associated with disease progression in patients with mild Crohn’s disease

Characteristic

Total (n = 104)

Patients with bowel damage (n = 47)

Patients without bowel damage (n = 57)

P value

Age at diagnosis, year, median (IQR)

28.0 (11.8)

32.0 (13.0)

24.0 (9.0)

0.047

Gender, (%)

   

0.067

 Male

85 (81.7)

42 (89.4)

43 (75.4)

 

 Female

19 (18.3)

5 (8.6)

14 (24.6)

 

Symptom duration before diagnosis, month, median (IQR)

15.9 (40.1)

36.0 (66.9)

11.1 (22.2)

<0.001

Location, (%)

   

0.431

 L1 (ileal)

20 (19.2)

12 (25.5)

8 (14.0)

 

 L2 (colonic)

4 (3.8)

1 (2.1)

3 (5.3)

 

 L3 (ileocolonic)

45 (43.3)

19 (40.4)

26 (45.6)

 

 L4 (only upper GI)

0 (0.0)

0 (0.0)

0 (0.0)

 

 L1–L4

11 (10.6)

5 (10.6)

6 (10.5)

 

 L2–L4

0 (0.0)

0 (0.0)

0 (0.0)

 

 L3–L4

24 (23.1)

10 (21.3)

14 (24.6)

 

Behavior at diagnosis, (%)

   

0.002

 B1 (non-stricturing, non-penetrating)

23 (22.1)

0 (0.0)

23 (22.1)

 

 B2 (stricturing)

11 (10.6)

11 (10.6)

0 (0.0)

 

 B3 (penetrating)

18 (17.3)

18 (17.3)

0 (0.0)

 

 B1-P

34 (32.7)

0 (0.0)

34 (32.7)

 

 B2-P

8 (7.7)

8 (7.7)

0 (0.0)

 

 B3-P

10 (9.6)

10 (9.6)

0 (0.0)

 

BMI, median (IQR)

19.7 (3.7)

19.2 (3.9)

20.3 (3.6)

0.206

CRP, median (IQR)

1.6 (3.6)

1.6 (3.6)

1.6 (3.6)

0.268

ESR, median (IQR)

38.0 (50.5)

32.0 (49.0)

30.0 (58.0)

0.981

Hct, median (IQR)

39.5 (6.9)

39.1 (7.0)

39.9 (6.9)

0.800

CDAI, median (IQR)

180.4 (36.6)

187.4 (40.2)

177.6 (36.3)

0.975

  1. IQR inter-quartile range, ASA aminosalicylic acid, BMI body mass index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, Hct hematocrit, CDAI Crohn’s disease activity index, NA not applicable